Effects of tolcapone on working memory and brain activity in abstinent smokers: A proof-of-concept study

Drug and Alcohol Dependence

Volumn 133, Issue 3, 2013, Pages 852-856

  Ashare, Rebecca L ^a   Wileyto, E Paul ^a,b   Ruparel, Kosha ^a   Goelz, Patricia M ^a   Hopson, Ryan D ^a   Valdez, Jeffrey N ^a   Gur, Ruben C ^a   Loughead, James ^a   Lerman, Caryn ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

COMT; FMRI; Nicotine; Smoking; Tolcapone; Working memory

Indexed keywords

CATECHOL METHYLTRANSFERASE; PLACEBO; TOLCAPONE;

ADULT; ALLELE; ARTICLE; BOLD SIGNAL; BRAIN REGION; CLINICAL ARTICLE; COGNITIVE DEFECT; COMT GENE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SMOKING CESSATION; TREATMENT OUTCOME; WORKING MEMORY;

COMT; FMRI; NICOTINE; SMOKING; TOLCAPONE; WORKING MEMORY;

ADOLESCENT; ADULT; AFFECT; AGED; BEHAVIOR, ADDICTIVE; BENZOPHENONES; BRAIN; BRAIN MAPPING; CATECHOL O-METHYLTRANSFERASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; NITROPHENOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE CESSATION PRODUCTS; YOUNG ADULT;

EID: 84888434236     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.09.003     Document Type: Article

References (42)

1. Apud J.A., Mattay V., Chen J., Kolachana B.S., Callicott J.H., Rasetti R., Alce G., Iudicello J.E., Akbar N., Egan M.F., Goldberg T.E., Weinberger D.R. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007, 32:1011-1020.
2. Arnsten A.F.T. Stress signalling pathways that impair prefrontal cortex structure and function. Nat. Rev. Neurosci. 2009, 10:410-422.
3. Barnett J.H., Scoriels L., Munafo M.R. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol. Psychiatry 2008, 64:137-144.
4. Chein J.M., Schneider W. Neuroimaging studies of practice-related change: fMRI and meta-analytic evidence of a domain-general control network for learning. Cogn. Brain Res. 2005, 25:607-623.
5. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
6. Colilla S., Lerman C., Shields P.G., Jepson C., Rukstalis M., Berlin J., DeMichele A., Bunin G., Strom B.L., Rebbeck T.R. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet. Genomics 2005, 15:393.
7. Cox L.S., Tiffany S.T., Christen A.G. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob. Res. 2001, 3:7-16.
8. Dennis N.A., Need A.C., LaBar K.S., Waters-Metenier S., Cirulli E.T., Kragel J., Goldstein D.B., Cabeza R. COMT Val108/158Met genotype affects neural but not cognitive processing in healthy individuals. Cereb. Cortex 2010, 20:672-683.
9. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6917-6922.
10. Falcone M., Wileyto E.P., Ruparel K., Gerraty R.T., Laprate L., Detre J.A., Gur R., Loughead J., Lerman C. Age-related differences in working memory deficits during nicotine withdrawal. Addict. Biol. 2013, (Epub ahead of print).
11. Farrell S.M., Tunbridge E.M., Braeutigam S., Harrison P.J. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol. Psychiatry 2012, 71:538-544.
12. Giakoumaki S.G., Roussos P., Bitsios P. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 2008, 33:3058-3068.
13. Goldberg T.E., Weinberger D.R. Genes and the parsing of cognitive processes. Trends Cogn. Sci. 2004, 8:325-335.
14. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berlin) 2004, 174:3-16.
15. Grieder T.E., George O., Tan H., George S.R., Le Foll B., Laviolette S.R., van der Kooy D. Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3101-3106.
16. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict. 1991, 86:1119-1127.
17. Hendricks P., Ditre J., Drobes D., Brandon T. The early time course of smoking withdrawal effects. Psychopharmacology (Berlin) 2006, 187:385-396.
18. Hughes J., Hatsukami D., Pickens R., Krahn D., Malin S., Luknic A. Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berlin) 1984, 83:82-87.
19. Hughes J.R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob. Res. 2007, 9:315-327.
20. Jenkinson M., Bannister P., Brady M., Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002, 17:825-841.
21. Jenkinson M., Smith S. A global optimisation method for robust affine registration of brain images. Med. Image Anal. 2001, 5:143-156.
22. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
23. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210.
24. Loughead J., Ray R., Wileyto E.P., Ruparel K., Sanborn P., Siegel S., Gur R.C., Lerman C. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol. Psychiatry 2010, 67:715-721.
25. Loughead J., Wileyto E.P., Valdez J.N., Sanborn P., Tang K., Strasser A.A., Ruparel K., Ray R., Gur R.C., Lerman C. Effect of abstinence challenge on brain function and cognition in smokers differs by COMT genotype. Mol. Psychiatry 2009, 14:820-826.
26. Munafo M.R., Johnstone E.C., Guo B., Murphy M.F., Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet. Genomics 2008, 18:121-128.
27. Mutschler J., Abbruzzese E., von der Goltz C., Dinter C., Mobascher A., Thiele H., Diaz-Lacava A., Dahmen N., Gallinat J., Majic T., Petrovsky N., Thuerauf N., Kornhuber J., Grunder G., Rademacher L., Brinkmeyer J., Wienker T., Wagner M., Winterer G., Kiefer F. Lack of association of a functional catechol-o-methyltransferase gene polymorphism with risk of tobacco smoking: results from a multicenter case-control study. Nicotine Tob. Res. 2013, 15(7):1322-1327.
28. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 2005, 8:1445-1449.
29. Omidvar M., Stolk L., Uitterlinden A.G., Hofman A., Van Duijn C.M., Tiemeier H. The effect of catechol-O-methyltransferase Met/Val functional polymorphism on smoking cessation: retrospective and prospective analyses in a cohort study. Pharmacogenet. Genomics 2009, 19:45-51.
30. Patterson F., Jepson C., Loughead J., Perkins K., Strasser A., Siegel S., Frey J., Gur R., Lerman C. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend. 2010, 106:61-64.
31. Patterson F., Jepson C., Strasser A.A., Loughead J., Perkins K.A., Gur R.C., Frey J.M., Siegel S., Lerman C. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychiatry 2009, 65:144-149.
32. Perkins K.A., Lerman C., Stitzer M., Fonte C.A., Briski J.L., Scott J.A., Chengappa K.N. Development of procedures for early screening of smoking cessation medications in humans. Clin. Pharmacol. Ther. 2008, 84:216-221.
33. Sankoh A.J., Huque M.F., Dubey S.D. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat. Med. 1997, 16:2529-2542.
34. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33. quiz 34-57.
35. Smith S.M. Fast robust automated brain extraction. Hum. Brain Mapp. 2002, 17:143-155.
36. Stokes P.R., Rhodes R.A., Grasby P.M., Mehta M.A. The effects of the COMT Val108/158Met polymorphism on BOLD activation during working memory, planning, and response inhibition: a role for the posterior cingulate cortex?. Neuropsychopharmacology 2011, 36:763-771.
37. van Raalten T.R., Ramsey N.F., Duyn J., Jansma J.M. Practice induces function-specific changes in brain activity. PLoS ONE 2008, 3:e3270.
38. Wardle M.C., de Wit H., Penton-Voak I., Lewis G., Munafo M.R. Lack of association between COMT and working memory in a population-based cohort of healthy young adults. Neuropsychopharmacology 2013, 38:1253-1263.
39. Watson D., Clark L.A., Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J. Pers. Soc. Psychol. 1988, 54:1063-1070.
40. Woolrich M.W., Ripley B.D., Brady M., Smith S.M. Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage 2001, 14:1370-1386.
41. Zachary R.S. Shipley Institute of Living Scale - Revised Manual 2000, Western Psychological Services, Los Angeles.
42. Zhang L., Dong Y., Doyon W.M., Dani J.A. Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens. Biol. Psychiatry 2012, 71:184-191.